Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Transforming activity and therapeutic targeting of C-terminal-binding protein 2 in Apc-mutated neoplasia.

Sumner ET, Chawla AT, Cororaton AD, Koblinski JE, Kovi RC, Love IM, Szomju BB, Korwar S, Ellis KC, Grossman SR.

Oncogene. 2017 Aug 17;36(33):4810-4816. doi: 10.1038/onc.2017.106. Epub 2017 Apr 17.

2.

APC mutations in colorectal tumours from FAP patients are selected for CtBP-mediated oligomerization of truncated APC.

Schneikert J, Brauburger K, Behrens J.

Hum Mol Genet. 2011 Sep 15;20(18):3554-64. doi: 10.1093/hmg/ddr273. Epub 2011 Jun 10.

PMID:
21665989
3.

Adenomatous polyposis coli control of C-terminal binding protein-1 stability regulates expression of intestinal retinol dehydrogenases.

Nadauld LD, Phelps R, Moore BC, Eisinger A, Sandoval IT, Chidester S, Peterson PW, Manos EJ, Sklow B, Burt RW, Jones DA.

J Biol Chem. 2006 Dec 8;281(49):37828-35. Epub 2006 Oct 6.

4.
5.

An intestinal stem cell niche in Apc mutated neoplasia targetable by CtBP inhibition.

Chawla AT, Cororaton AD, Idowu MO, Damle PK, Szomju B, Ellis KC, Patel BB, Grossman SR.

Oncotarget. 2018 Aug 21;9(65):32408-32418. doi: 10.18632/oncotarget.25784. eCollection 2018 Aug 21.

6.

A two-step model for colon adenoma initiation and progression caused by APC loss.

Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K, Broadbent T, Sarkar S, Burt RW, Jones DA.

Cell. 2009 May 15;137(4):623-34. doi: 10.1016/j.cell.2009.02.037.

7.

A targeted constitutive mutation in the APC tumor suppressor gene underlies mammary but not intestinal tumorigenesis.

Gaspar C, Franken P, Molenaar L, Breukel C, van der Valk M, Smits R, Fodde R.

PLoS Genet. 2009 Jul;5(7):e1000547. doi: 10.1371/journal.pgen.1000547. Epub 2009 Jul 3.

8.

Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.

Birts CN, Harding R, Soosaipillai G, Halder T, Azim-Araghi A, Darley M, Cutress RI, Bateman AC, Blaydes JP.

Biol Cell. 2010 Jan;103(1):1-19. doi: 10.1042/BC20100067.

9.

Targeted suppression of beta-catenin blocks intestinal adenoma formation in APC Min mice.

Foley PJ, Scheri RP, Smolock CJ, Pippin J, Green DW, Drebin JA.

J Gastrointest Surg. 2008 Aug;12(8):1452-8. doi: 10.1007/s11605-008-0519-6. Epub 2008 Jun 3.

PMID:
18521697
10.

Functional comparison of human adenomatous polyposis coli (APC) and APC-like in targeting beta-catenin for degradation.

Schneikert J, Vijaya Chandra SH, Ruppert JG, Ray S, Wenzel EM, Behrens J.

PLoS One. 2013 Jul 1;8(7):e68072. doi: 10.1371/journal.pone.0068072. Print 2013.

11.

Inhibition of C-terminal binding protein attenuates transcription factor 4 signaling to selectively target colon cancer stem cells.

Patel J, Baranwal S, Love IM, Patel NJ, Grossman SR, Patel BB.

Cell Cycle. 2014;13(22):3506-18. doi: 10.4161/15384101.2014.958407.

12.

Adenomatous polyposis coli (APC) membrane recruitment 3, a member of the APC membrane recruitment family of APC-binding proteins, is a positive regulator of Wnt-β-catenin signalling.

Brauburger K, Akyildiz S, Ruppert JG, Graeb M, Bernkopf DB, Hadjihannas MV, Behrens J.

FEBS J. 2014 Feb;281(3):787-801. doi: 10.1111/febs.12624. Epub 2013 Dec 12.

13.

Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells.

Yang J, Zhang W, Evans PM, Chen X, He X, Liu C.

J Biol Chem. 2006 Jun 30;281(26):17751-7. Epub 2006 May 3.

14.

Rapamycin inhibition of polyposis and progression to dysplasia in a mouse model.

Hardiman KM, Liu J, Feng Y, Greenson JK, Fearon ER.

PLoS One. 2014 Apr 24;9(4):e96023. doi: 10.1371/journal.pone.0096023. eCollection 2014.

15.

Vitamin D receptor deficiency enhances Wnt/β-catenin signaling and tumor burden in colon cancer.

Larriba MJ, Ordóñez-Morán P, Chicote I, Martín-Fernández G, Puig I, Muñoz A, Pálmer HG.

PLoS One. 2011;6(8):e23524. doi: 10.1371/journal.pone.0023524. Epub 2011 Aug 15.

16.

Haploinsufficiency of Krüppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis.

Ghaleb AM, McConnell BB, Nandan MO, Katz JP, Kaestner KH, Yang VW.

Cancer Res. 2007 Aug 1;67(15):7147-54.

17.

Ovarian steroid cell tumor with biallelic adenomatous polyposis coli inactivation in a patient with familial adenomatous polyposis.

Hu PJ, Knoepp SM, Wu R, Cho KR.

Genes Chromosomes Cancer. 2012 Mar;51(3):283-9. doi: 10.1002/gcc.20953. Epub 2011 Nov 25.

18.

Active-Site Tryptophan, the Target of Antineoplastic C-Terminal Binding Protein Inhibitors, Mediates Inhibitor Disruption of CtBP Oligomerization and Transcription Coregulatory Activities.

Dcona MM, Damle PK, Zarate-Perez F, Morris BL, Nawaz Z, Dennis MJ, Deng X, Korwar S, Singh SJ, Ellis KC, Royer WE, Bandyopadhyay D, Escalante C, Grossman SR.

Mol Pharmacol. 2019 Jul;96(1):99-108. doi: 10.1124/mol.118.114363. Epub 2019 Apr 29.

PMID:
31036695
19.

Loss of a single Hic1 allele accelerates polyp formation in Apc(Δ716) mice.

Mohammad HP, Zhang W, Prevas HS, Leadem BR, Zhang M, Herman JG, Hooker CM, Watkins DN, Karim B, Huso DL, Baylin SB.

Oncogene. 2011 Jun 9;30(23):2659-69. doi: 10.1038/onc.2010.633. Epub 2011 Feb 7.

20.

Inhibition of intestinal polyposis with reduced angiogenesis in ApcMin/+ mice due to decreases in c-Myc expression.

Yekkala K, Baudino TA.

Mol Cancer Res. 2007 Dec;5(12):1296-303. doi: 10.1158/1541-7786.MCR-07-0232. Erratum in: Mol Cancer Res. 2008 Feb;6(2):340.

Supplemental Content

Support Center